close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard
Home惻Aandelen Lijst惻BioArctic AB
Search

BioArctic AB

Gesloten

265.6 -0.75

Prijsupdate 11 nov 2025, 16:24 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

255

Max

269

Belangrijke statistieken

By Trading Economics

Inkomsten

-896M

179M

Verkoop

-897M

392M

K/W

Sectorgemiddelde

24.328

77.256

EPS

1.09

Winstmarge

45.668

Werknemers

119

EBITDA

-893M

188M

Marktinformatie

By TradingEconomics

Marktkapitalisatie

5.1B

26B

Vorige openingsprijs

266.35

Vorige sluitingsprijs

265.6

BioArctic AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 nov 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

DJ

Lezen

11 nov 2025, 22:21 UTC

Winsten

Aristocrat Boosts Dividend as Annual Profit Rises 12%

DJ

Lezen

11 nov 2025, 23:52 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

DJ

Lezen

11 nov 2025, 23:44 UTC

Winsten

Singtel's 1H Net Profit Surges

DJ

Lezen

11 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

DJ

Lezen

11 nov 2025, 23:18 UTC

Winsten

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

DJ

Lezen

11 nov 2025, 23:15 UTC

Winsten

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

DJ

Lezen

11 nov 2025, 23:14 UTC

Winsten

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

DJ

Lezen

11 nov 2025, 23:12 UTC

Winsten

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

DJ

Lezen

11 nov 2025, 23:11 UTC

Winsten

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

DJ

Lezen

11 nov 2025, 23:10 UTC

Winsten

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

DJ

Lezen

11 nov 2025, 23:04 UTC

Marktinformatie

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

DJ

Lezen

11 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

11 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Health Care Roundup: Market Talk

DJ

Lezen

11 nov 2025, 21:46 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

DJ

Lezen

11 nov 2025, 21:41 UTC

Winsten

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

DJ

Lezen

11 nov 2025, 21:40 UTC

Winsten

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

DJ

Lezen

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

DJ

Lezen

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

DJ

Lezen

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

DJ

Lezen

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

DJ

Lezen

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: Final Dividend 49 Australian Cents/Share

DJ

Lezen

11 nov 2025, 21:37 UTC

Winsten

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

DJ

Lezen

11 nov 2025, 21:36 UTC

Winsten

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

DJ

Lezen

11 nov 2025, 21:35 UTC

Winsten

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

DJ

Lezen

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Adj EPS 79c >ALC

DJ

Lezen

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Rev $2.61B >ALC.EB

DJ

Lezen

11 nov 2025, 21:35 UTC

Winsten

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

DJ

Lezen

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q EPS 48c >ALC.EB

DJ

Lezen

11 nov 2025, 21:34 UTC

Winsten

Alcon Backs 2025 Adj EPS $3.05-Adj EPS $3.15 >ALC

DJ

Lezen

BioArctic AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
help-icon Live chat